|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Although only two cases showed immunohistochemical evidence of B-cell lineage (CD20+), all five cases were documented as B-cell lymphomas on the basis of the clonal immunoglobulin heavychain gene rearrangement, as demonstrated by polymerase chain reaction (PCR) in all the cases and by Southern blot hybridization in three cases; all cases were negative for T-cell markers, and three cases showed germline configuration for T-cell receptor beta-chain.
|
8772789 |
1996 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Paracentesis followed by immunophenotyping, karyotyping, and molecular studies allowed us to diagnose a small noncleaved B-cell lymphoma (CD20+, CD24+, CD10+, CD5-, CD23-, lambda+) with the t(8;22) (q24;q11) translocation and clonal rearrangement of the immunoglobulin heavy chain gene.
|
9013840 |
1997 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
The T and B cell lymphomas and the nasopharyngeal carcinoma in nude mice were derived from human nasopharyngeal mucosa; this was proved by using human specific monoclonal antibodies to CD3 for T cells, to CD20 for B cells, and to epithelial membrane antigen for epithelial cells.
|
9829857 |
1998 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
|
10100713 |
1999 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for cancer treatment using immunoconjugates or bi-specific antibodies.
|
10343908 |
1999 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
This is the first report demonstrating the safety and efficacy of Rituxan anti-CD20 chimeric antibody in combination with standard-dose systemic chemotherapy in the treatment of indolent B-cell lymphoma.
|
10458242 |
1999 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings may indicate that anti-CD20 immunotherapy could be of value in high-grade B-cell lymphomas.
|
10554835 |
1999 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-CD20 monoclonal antibody therapy in Epstein-Barr Virus-associated B cell lymphoma following lung transplantation.
|
10808158 |
2000 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
This is the first report to demonstrate the safety and efficacy of the Rituxan chimeric anti-CD20 antibody in combination with standard-dose CHOP in the treatment of aggressive B-cell lymphoma.
|
11208830 |
2001 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Rituximab (Rituxan; Genentech, Inc, South San Francisco, CA and IDEC Pharmaceutical Corporation, San Diego, CA) is an effective agent for the treatment of CD20-positive B-cell lymphomas.
|
11225999 |
2000 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite wide use of the anti-CD20 monoclonal antibody rituximab in the treatment of B cell lymphomas, the mechanism by which it causes B cell depletion remains a subject of controversy.
|
12571855 |
2003 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
We consider that this case confirms the existence of ALK(+), CD30(-), CD20(-) large B-cell lymphomas proposed by Delsol et al.
|
12920229 |
2003 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal anti-CD20 antibody (rituximab) is active, but not curative, therapy for B-cell non-Hodgkin's lymphoma.
|
15634664 |
2004 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
|
15665303 |
2005 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
All 11 BCLs presented positive staining for CD20 and CD79a but negative for other antibodies.
|
16360416 |
2006 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
There has been interest in generating T cells expressing chimeric artificial receptors (CARs) targeting CD19/CD20 antigens to treat B-cell lymphomas.
|
16926291 |
2006 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This paradigmatic case suggests that CD20-expression reappearance after purging of CD20-positive clones with rituximab might be an underestimated occurrence in B-cell lymphomas.
|
17405748 |
2007 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy.
|
17675267 |
2007 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.
|
17712791 |
2008 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Rituximab, an anti-CD20 monoclonal antibody, is widely used in the treatment of B-cell lymphoma.
|
17949786 |
2008 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
With the now well-accepted addition of rituximab (anti-CD20 antibody) to the typical large B-cell lymphoma chemotherapeutic regimen, a revalidation of any survival differences between the large B-cell lymphoma subgroups is necessary.
|
18181663 |
2008 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
We report the results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T-cell receptor and neomycin resistance gene.
|
18509084 |
2008 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Knowledge of the unusual phenomenon of CD20 expression in TCL, in conjunction with careful morphologic analysis, the use of a panel of antibodies, and molecular genetic studies, is important in avoiding a misdiagnosis of BCL.
|
18753947 |
2008 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
In human whole blood, most of the added CD20(+) B-cell lymphoma died shortly, within 4 hours, irrespective of the presence or absence of anti-CD20.
|
19218011 |
2009 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we report that a CD20-negative phenotypic change after chemotherapies with rituximab occurs in a certain number of CD20-positive B-cell lymphoma patients.
|
19246561 |
2009 |